Presented research from Mayo Clinic proves TetraGraph ease of use

Postoperative residual weakness continues to be a patient safety threat and quantitative neuromuscular monitors such as the TetraGraph are recommended as an evidence-based approach to confirming adequate recovery of neuromuscular function postoperatively and reduce possible complications related to residual weakness. The study investigated how long it took an experienced nurse anesthetist to apply and utilize various neuromuscular devices, as well as their perception regarding the ease of application of these.  "It takes a relatively minimal additional time to apply a quantitative monitor which is much more precise compared to a peripheral nerve stimulator. Among the two quantitative monitors in the study, application of the Philips IntelliVue NMT was slightly faster than the TetraGraph however TOF ratios where obtained faster and easier with TetraGraph. It’s important to remember that participants were used to applying the Philips device while they had no prior exposure to the TetraGraph. The recent FDA-approval of TetraGraph will undoubtedly increase the use of this device. Utilization of both devices was found to be relatively straightforward "says J.Ross Renew, Assistant Professor at the Mayo Clinic in Jacksonville, FL.

Over 70 million patients undergo surgery every year using both anesthetic and muscle relaxant drugs and research has shown that over 30 percent suffer from postoperative complications if objective patient monitoring is missing.

TetraGraph is a unique CE- and FDA-cleared monitoring system that has been developed to help reduce postoperative complications with a cost-effective and user-friendly solution. TetraGraph is a digital system that stimulates a peripheral nerve and measures, analyzes with proprietary algorithms and displays real-time muscle function in surgical patients receiving neuromuscular blocking drugs (NMBAs) as part of their general anesthesia.

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                          

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com       

TO THE EDITORS

About Senzime

Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients ' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se, is Certified Adviser for Senzime. www.senzime.com